# SenesTech, Inc.: financial statements, quarterly

SNES · Nasdaq · CIK 1680378 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/snes.md) · [Financials](/companies/snes/financials.md) · [Filings](/companies/snes/filings.md) · [Insiders](/companies/snes/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/snes/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [360](/filings/0001628280-24-047314.md) | [295 d](/filings/0001628280-25-012408.md) | [415](/filings/0001628280-25-023925.md) | [459](/filings/0001628280-25-039024.md) | [482](/filings/0001628280-25-051177.md) | [501 d](/filings/0001628280-26-017384.md) | [485](/filings/0001628280-26-034244.md) | [625](/filings/0001628280-26-053602.md) | [690](/filings/0001628280-25-051177.md) | [421 d](/filings/0001628280-26-017384.md) | [493](/filings/0001628280-26-034244.md) | [770](/filings/0001628280-26-053602.md) |
| Cost of revenue | $k | [184](/filings/0001628280-24-047314.md) | [166 d](/filings/0001628280-25-012408.md) | [280](/filings/0001628280-25-023925.md) | [210](/filings/0001628280-25-039024.md) | [167](/filings/0001628280-25-051177.md) | [196 d](/filings/0001628280-26-017384.md) | [172](/filings/0001628280-26-034244.md) | [216](/filings/0001628280-26-053602.md) | [257](/filings/0001628280-25-051177.md) | [188 d](/filings/0001628280-26-017384.md) | [155](/filings/0001628280-26-034244.md) | [203](/filings/0001628280-26-053602.md) |
| Gross profit | $k | [176](/filings/0001628280-24-047314.md) | [129 d](/filings/0001628280-25-012408.md) | [135](/filings/0001628280-25-023925.md) | [249](/filings/0001628280-25-039024.md) | [315](/filings/0001628280-25-051177.md) | [305 d](/filings/0001628280-26-017384.md) | [313](/filings/0001628280-26-034244.md) | [409](/filings/0001628280-26-053602.md) | [433](/filings/0001628280-25-051177.md) | [233 d](/filings/0001628280-26-017384.md) | [338](/filings/0001628280-26-034244.md) | [567](/filings/0001628280-26-053602.md) |
| Research and development | $k | [379](/filings/0001628280-24-047314.md) | [81.0 d](/filings/0001628280-25-012408.md) | [370](/filings/0001628280-25-023925.md) | [467](/filings/0001628280-25-039024.md) | [451](/filings/0001628280-25-051177.md) | [424 d](/filings/0001628280-26-017384.md) | [418](/filings/0001628280-26-034244.md) | [427](/filings/0001628280-26-053602.md) | [400](/filings/0001628280-25-051177.md) | [453 d](/filings/0001628280-26-017384.md) | [422](/filings/0001628280-26-034244.md) | [377](/filings/0001628280-26-053602.md) |
| Operating income | $k | [(1,951)](/filings/0001628280-24-047314.md) | [(1,736) d](/filings/0001628280-25-012408.md) | [(1,843)](/filings/0001628280-25-023925.md) | [(1,602)](/filings/0001628280-25-039024.md) | [(1,547)](/filings/0001628280-25-051177.md) | [(1,257) d](/filings/0001628280-26-017384.md) | [(1,663)](/filings/0001628280-26-034244.md) | [(1,614)](/filings/0001628280-26-053602.md) | [(1,347)](/filings/0001628280-25-051177.md) | [(1,881) d](/filings/0001628280-26-017384.md) | [(2,119)](/filings/0001628280-26-034244.md) | [(1,862)](/filings/0001628280-26-053602.md) |
| Net income | $k | [(1,947)](/filings/0001628280-24-047314.md) | [(1,733) d](/filings/0001628280-25-012408.md) | [(1,832)](/filings/0001628280-25-051177.md) | [(1,584)](/filings/0001628280-25-051177.md) | [(1,513)](/filings/0001628280-25-051177.md) | [(1,255) d](/filings/0001628280-26-017384.md) | [(1,665)](/filings/0001628280-26-053602.md) | [(1,616)](/filings/0001628280-26-053602.md) | [(1,298)](/filings/0001628280-25-051177.md) | [(1,804) d](/filings/0001628280-26-017384.md) | [(2,063)](/filings/0001628280-26-053602.md) | [(1,832)](/filings/0001628280-26-053602.md) |
| Diluted EPS | $ per share | [(55.93)](/filings/0001628280-24-047314.md) | not reported | [(3.56)](/filings/0001628280-25-023925.md) | [(3.08)](/filings/0001628280-25-039024.md) | [(2.07)](/filings/0001628280-25-051177.md) | not reported | [(1.28)](/filings/0001628280-26-034244.md) | [(0.87)](/filings/0001628280-26-053602.md) | [(0.28)](/filings/0001628280-25-051177.md) | not reported | [(0.39)](/filings/0001628280-26-034244.md) | [(0.35)](/filings/0001628280-26-053602.md) |
| Basic EPS | $ per share | [(55.93)](/filings/0001628280-24-047314.md) | not reported | [(3.56)](/filings/0001628280-25-023925.md) | [(3.08)](/filings/0001628280-25-039024.md) | [(2.07)](/filings/0001628280-25-051177.md) | not reported | [(1.28)](/filings/0001628280-26-034244.md) | [(0.87)](/filings/0001628280-26-053602.md) | [(0.28)](/filings/0001628280-25-051177.md) | not reported | [(0.39)](/filings/0001628280-26-034244.md) | [(0.35)](/filings/0001628280-26-053602.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.1](/filings/0001628280-23-038343.md) | [5.4](/filings/0001628280-25-012408.md) | [3.6](/filings/0001628280-24-022348.md) | [2.0](/filings/0001628280-24-036248.md) | [2.5](/filings/0001628280-24-047314.md) | [1.3](/filings/0001628280-26-017384.md) | [1.7](/filings/0001628280-25-023925.md) | [6.1](/filings/0001628280-25-039024.md) | [7.3](/filings/0001628280-25-051177.md) | [7.6](/filings/0001628280-26-053602.md) | [6.8](/filings/0001628280-26-034244.md) | [5.1](/filings/0001628280-26-053602.md) |
| Current assets | $m | [3.3](/filings/0001628280-23-038343.md) | [6.7](/filings/0001628280-25-012408.md) | [4.9](/filings/0001628280-24-022348.md) | [3.6](/filings/0001628280-24-036248.md) | [4.0](/filings/0001628280-24-047314.md) | [2.8](/filings/0001628280-26-017384.md) | [3.2](/filings/0001628280-25-023925.md) | [7.5](/filings/0001628280-25-039024.md) | [11.8](/filings/0001628280-25-051177.md) | [10.1](/filings/0001628280-26-053602.md) | [8.4](/filings/0001628280-26-034244.md) | [6.8](/filings/0001628280-26-053602.md) |
| Total assets | $m | [3.9](/filings/0001628280-23-038343.md) | [7.3](/filings/0001628280-25-012408.md) | [5.5](/filings/0001628280-24-022348.md) | [4.0](/filings/0001628280-24-036248.md) | [4.4](/filings/0001628280-24-047314.md) | [3.3](/filings/0001628280-26-017384.md) | [3.6](/filings/0001628280-25-023925.md) | [10.4](/filings/0001628280-25-039024.md) | [14.6](/filings/0001628280-25-051177.md) | [12.8](/filings/0001628280-26-053602.md) | [11.1](/filings/0001628280-26-034244.md) | [9.4](/filings/0001628280-26-053602.md) |
| Current liabilities | $m | [1.0](/filings/0001628280-23-038343.md) | [0.8](/filings/0001628280-25-012408.md) | [0.7](/filings/0001628280-24-022348.md) | [0.8](/filings/0001628280-24-036248.md) | [0.6](/filings/0001628280-24-047314.md) | [0.6](/filings/0001628280-26-017384.md) | [0.5](/filings/0001628280-25-023925.md) | [0.8](/filings/0001628280-25-039024.md) | [0.7](/filings/0001628280-25-051177.md) | [0.8](/filings/0001628280-26-053602.md) | [0.9](/filings/0001628280-26-034244.md) | [1.0](/filings/0001628280-26-053602.md) |
| Total liabilities | $m | [1.1](/filings/0001628280-23-038343.md) | [0.9](/filings/0001628280-25-012408.md) | [0.9](/filings/0001628280-24-022348.md) | [0.9](/filings/0001628280-24-036248.md) | [0.8](/filings/0001628280-24-047314.md) | [0.8](/filings/0001628280-26-017384.md) | [0.7](/filings/0001628280-25-023925.md) | [3.4](/filings/0001628280-25-039024.md) | [3.3](/filings/0001628280-25-051177.md) | [3.3](/filings/0001628280-26-053602.md) | [3.4](/filings/0001628280-26-034244.md) | [3.4](/filings/0001628280-26-053602.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2.8](/filings/0001628280-24-047314.md) | [6.4](/filings/0001628280-26-017384.md) | [4.6](/filings/0001628280-25-051177.md) | [3.1](/filings/0001628280-25-051177.md) | [3.7](/filings/0001628280-25-051177.md) | [2.5](/filings/0001628280-26-053602.md) | [2.9](/filings/0001628280-26-053602.md) | [7.0](/filings/0001628280-26-053602.md) | [11.3](/filings/0001628280-25-051177.md) | [9.6](/filings/0001628280-26-053602.md) | [7.7](/filings/0001628280-26-053602.md) | [6.1](/filings/0001628280-26-053602.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,790) d](/filings/0001628280-24-047314.md) | [(2,019) d](/filings/0001628280-25-012408.md) | [(1,829)](/filings/0001628280-25-023925.md) | [(1,587) d](/filings/0001628280-25-039024.md) | [(1,399) d](/filings/0001628280-25-051177.md) | [(1,218) d](/filings/0001628280-26-017384.md) | [(1,557)](/filings/0001628280-26-034244.md) | [(1,150) d](/filings/0001628280-26-053602.md) | [(1,379) d](/filings/0001628280-25-051177.md) | [(1,664) d](/filings/0001628280-26-017384.md) | [(1,929)](/filings/0001628280-26-034244.md) | [(1,709) d](/filings/0001628280-26-053602.md) |
| Capital expenditure | $k | [93.0 d](/filings/0001628280-24-047314.md) | [35.0 d](/filings/0001628280-25-012408.md) | [2.0](/filings/0001628280-25-023925.md) | [39.0 d](/filings/0001628280-25-039024.md) | [28.0 d](/filings/0001628280-25-051177.md) | [15.0 d](/filings/0001628280-26-017384.md) | [36.0](/filings/0001628280-26-034244.md) | [47.0 d](/filings/0001628280-26-053602.md) | [42.0 d](/filings/0001628280-25-051177.md) | [13.0 d](/filings/0001628280-26-017384.md) | [0.0](/filings/0001628280-26-034244.md) | [0.0 d](/filings/0001628280-26-053602.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [611](/filings/0001628280-23-038343.md) | [171](/filings/0001628280-24-022348.md) | [23.8](/filings/0001628280-24-036248.md) | [34.8](/filings/0001628280-24-047314.md) | [514](/filings/0001628280-25-023925.md) | [514](/filings/0001628280-25-039024.md) | [729](/filings/0001628280-25-051177.md) | [1,300](/filings/0001628280-26-034244.md) | [1,855](/filings/0001628280-26-053602.md) | [4,668](/filings/0001628280-25-051177.md) | [5,264](/filings/0001628280-26-034244.md) | [5,303](/filings/0001628280-26-053602.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,423,542 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053602.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.